Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

ClinicalTrials.gov ID: NCT00518895

Public ClinicalTrials.gov record NCT00518895. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind Study of Dacarbazine With or Without Genasense in Chemotherapy-naive Subjects With Advanced Melanoma and Low LDH (The AGENDA Trial)

Study identification

NCT ID
NCT00518895
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Genta Incorporated
Industry
Enrollment
300 participants

Conditions and interventions

Conditions

Interventions

  • dacarbazine plus Genasense Drug
  • dacarbazine plus placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2007
Primary completion
Apr 30, 2011
Completion
Apr 30, 2011
Last update posted
Nov 6, 2011

2007 – 2011

United States locations

U.S. sites
14
U.S. states
10
U.S. cities
14
Facility City State ZIP Site status
University of South Alabama Hospital, Mitchell Cancer Institute Mobile Alabama 36607
San Diego Pacific Oncology and Hematology Associates Inc. Encinitas California 92024
Redwood Regional Medical Group, Inc. Santa Rosa California 95403
Siouxland Hematology Oncology Associates Sioux City Iowa 51101
Dana Farber Cancer Institute Boston Massachusetts 02115
Hematology Oncology Centers of the Northern Rockies Billings Montana 59101
Morristown Memorial - Atlantic Healthcare System Morristown New Jersey 07960
Cancer Care Associates Oklahoma City Oklahoma 73112
Cancer Care Associates, Site 1 Tulsa Oklahoma 74104
St. Luke's Cancer Center Bethlehem Pennsylvania 18015
Thomas Jefferson University Hospital Philadelphia Pennsylvania 19107
The West Clinic Memphis Tennessee 38120
Texas Oncology - Sammons Cancer Center Dallas Texas 75246
MD Anderson Cancer Center at University of Texas Houston Texas 77030-4009

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00518895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 6, 2011 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00518895 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →